VA Office of Research and Development
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
The investigators will employ a double-blinded randomized placebo-controlled trial to determine the effects of 12 weeks of SGLT2 inhibition with empagliflozin (10 milligrams daily), or matching placebo, on arterial stiffness in Veterans with obesity. Fifty Veterans with obesity (BMI 30-45 kilograms per square meter), 30-60 years of age, will be recruited from the Harry S. Truman Memorial VA Hospital in Columbia, Missouri.
Inclusion Criteria: * Body mass index (BMI) 30-45 kilograms per square meter (kg/m2) * 30-60 years of age at randomization * Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030), or presence of Stage I hypertension or higher (PMID: 30354655), or current use of antihypertensive agents Exclusion Criteria: * Unable to provide consent * Diabetes mellitus * Uncontrolled hypertension (\>180/90 millimeters of mercury) or systolic \<100 millimeters of mercury at screening visit * Known history of cardiovascular disease: heart failure, i…
12 week treatment with 10mg empagliflozin daily
12 week treatment with 10mg placebo daily
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.